U.S Medical Robotics Market - 2025-2033

The U.S medical robotics market reached US$ 63.53 million in 2024 and is expected to reach US$ 286.99 million by 2033, growing at a CAGR of 16.2% during the forecast period 2025-2033.

Medical robotics, a combination of robotics, AI, and automation, improves healthcare delivery in surgery, rehabilitation, diagnostics, and hospital management. It enhances precision, reduces human error, and optimizes procedures, leading to better patient outcomes and operational efficiency. As the Application advances, it will transform medicine worldwide.

Market Dynamics: Drivers & Restraints

Advancements in Artificial Intelligence and Machine Learning

The U.S. medical robotics market is booming due to advancements in artificial intelligence and machine learning. These technologies improve precision, automation, and efficiency in robotic-assisted surgeries, reducing human error and improving patient outcomes. The integration of AI with medical robotics also enhances imaging, real-time analytics, and remote procedures, contributing to market growth in orthopedics, neurology, and general surgery.

For instance, in July 2024, Medtronic introduced its Live Stream function for the Touch Surgery digital technology ecosystem, featuring AI capabilities. The technology was used to assist in the removal of seeds from a red pepper by a Hugo surgical robot.

High Initial Investment and Maintenance Costs

Medical robotics adoption in the U.S. is hindered by high initial investment and maintenance costs, which include the acquisition of advanced surgical robotic systems, software updates, maintenance, and staff training. This financial burden, particularly for small and mid-sized hospitals, and reimbursement challenges and cost-effectiveness concerns limit the widespread adoption of robotic-assisted procedures, particularly in resource-limited healthcare settings.

For instance, the cost of surgical robots, such as the da Vinci Xi, Xi Si, CMR Surgical Versius, Stryker Mako, Zimmer Biomet ROSA, SSI Mantra, Asensus Senhance, Johnson & Johnson Monarch, NOAH Medical Galaxy, Intuitive Surgical Ion, Medtronic Hugo, and Globus Medical ExcelsiusGPS, is estimated to range between $1.5 million and $2.5 million.

Segment Analysis

The U.S medical robotics market is segmented based on product type, application, and end user.

Product Type:

The surgical robots segment is expected to dominate the U.S medical robotics market with the highest market share

Surgical robots are advanced medical devices that aid surgeons in complex procedures with precision, control, and minimal invasiveness. They integrate AI, machine learning, and high-definition imaging for real-time decision-making. Their ability to minimize trauma, reduce complications, and accelerate patient recovery has increased their adoption in healthcare institutions.

Moreover, surgical robots dominate the U.S. medical robotics market due to their precision, reduced complications, increase in FDA clearance and faster recovery times. Rehabilitation and hospital robots have limited applications, while hospital and pharmacy robots focus on physical therapy and post-stroke recovery.

For instance, in September 2024, THINK Surgical, Inc. received T MINI Miniature Robotic System 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use with the Persona The Personalized Knee System from Zimmer Biomet. ""T MINI addresses surgeon demand for ergonomic, wireless, handheld robotic systems, and we believe this will accelerate the adoption of robotics in knee procedures, particularly in the outpatient setting.

Hence, this FDA clearance is expected to boost the U.S. medical robotics market by promoting the use of compact, wireless robotic solutions in knee procedures.

Competitive Landscape

The major country players in the U.S medical robotics market include Intuitive Surgical, Stryker Corporation, Johnson & Johnson (Ethicon – Ottava), Medtronic Plc, Mendaera, Zimmer Biomet Holdings, Inc., Globus Medical Inc., Becton, Dickinson and Company, Diligent Robotics, and PROCEPT BioRobotics, among others.

Key Developments
• In December 2024, Microbot Medical submitted a 510(k) premarket notification to the US FDA for its Liberty endovascular robotic system, the world's first single-use, fully disposable robotic system for endovascular procedures. The submission follows a successful multicenter, single-arm trial to evaluate Liberty's performance and safety in human subjects undergoing peripheral vascular interventions.
• In November 2024, Johnson & Johnson MedTech received approval from the FDA for the OTTAVA robotic surgical system investigational device exemption, allowing the clinical trial to commence at U.S. sites. The company will now prepare sites, enroll patients, and begin surgical cases.

Why Purchase the Report?
• Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The U.S medical robotics market report delivers a detailed analysis with 72 key tables, more than 67 visually impactful figures, and 210 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Speciality Area & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.